The Study of Trilaciclib Combined With Chemotherapy On The Neoadjuvant Therapy of TNBC
To evaluate the efficacy and safety of trilaciclib combined with standard treatment project as a neoadjuvant treatment for triple negative breast cancer
Breast Neoplasm
DRUG: Trilaciclib plus chemotherapy|DRUG: Chemotherapy
The incidence of CIN, The incidence of ≥3 grade neutropenia, From date of randomization until the date of surgery, assessed up to 6 months
The incidence of CIT, The incidence of ≥3 grade thrombopenia, From date of randomization until the date of surgery, assessed up to 6 months|The incidence of CIA, The incidence of ≥3 grade anemia, From date of randomization until the date of surgery, assessed up to 6 months|pCR rate, Rate of pCR using the definition of ypT0/Tis ypN0 as assessed by the local pathologist., From date of randomization until the date of surgery, assessed up to 6 months.|ORR, Objective Response Rate, From date of randomization until the date of PD (up to 24 months)|OS, Overall survival, From date of randomization until the date of death(up to 24 months)|DFS, Disease-free survival, From date of randomization until the date of toxicity or PD (up to 24 months)|Adverse event, Number of participants with adverse events as a measure of safety and tolerability, Frame:From date of randomization until the date of toxicity or PD (up to 24 months)
Trilaciclib indication: Trilaciclib, a CDK4/6 inhibitor, was used before chemotherapy to reduce the incidence of bone marrow suppression and approved by the FDA for small cell lung cancer patients in 2021.